Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b/2b study investigating the safety and preliminary antitumor effects of
Sym004 in combination with nivolumab versus nivolumab monotherapy when administered every
second week.